Volastra Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Volastra Therapeutics's estimated annual revenue is currently $4.3M per year.
- Volastra Therapeutics's estimated revenue per employee is $77,500
- Volastra Therapeutics's total funding is $44M.
Employee Data
- Volastra Therapeutics has 55 Employees.
- Volastra Therapeutics grew their employee count by -11% last year.
Volastra Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Head Biochemistry | Reveal Email/Phone |
2 | SVP, CMC | Reveal Email/Phone |
3 | VP, Chemistry | Reveal Email/Phone |
4 | Controller | Reveal Email/Phone |
5 | VP, Head Biology | Reveal Email/Phone |
6 | VP, Head Immunology and Data Science | Reveal Email/Phone |
7 | Director, Biomarkers | Reveal Email/Phone |
8 | Chief Operating Officer | Reveal Email/Phone |
9 | Director, Business Development and Commercial | Reveal Email/Phone |
10 | Director, Biochemistry and Structural Biology | Reveal Email/Phone |
Volastra Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Volastra Therapeutics?
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient's CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.
keywords:N/A
$44M
Total Funding
55
Number of Employees
$4.3M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Volastra Therapeutics News
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting...
is pairing with New York-based biotech Volastra Therapeutics. The companies announced a multi-year R&D collaboration, with Bristol Myers...
Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery...
Volastra Therapeutics, a NYC-based biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, extended its original $12m seed round to a total of $44m. New investors Vida Ventures and Catalio Capital Management joined a syndicate that includes Polari ...
Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, today announced the extension of its original $12 million seed round to a total of $44 million. New investors Vida Ventures and Catalio Capital Management joined a syn ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.2M | 55 | 31% | $18.9M |
#2 | $10.1M | 55 | 15% | N/A |
#3 | $5.9M | 55 | 12% | N/A |
#4 | $9.9M | 55 | -4% | N/A |
#5 | $11.2M | 55 | 6% | N/A |